Risks for all-cause mortality, cancer-specific mortality, disease progression reduced for those quitting after diagnosis

No difference in overall survival seen with nivolumab plus ipilimumab, nivolumab alone for advanced, chemotherapy-pretreated disease

Objective response seen in 37.1 percent of patients with previously treated KRAS p.G12C-mutated non-small cell lung cancer

Any degree of aortic valve calcification was identified in 13.1 percent of participants; 0.5 percent had at least moderate AS

Lumakras is approved for use in adults with KRAS G12C-mutated non-small cell lung cancer

Risk for recurrence increased with surgical delay beyond 12 weeks; overall survival improved with surgery within 12 weeks

Efficacy data revealed 40 percent response rate, median response duration of 11.1 months

Deep learning algorithm could aid malignancy risk estimation of pulmonary nodules detected on low-dose screening CT

<p style="margin-left: 20px;">Progression-free survival significantly longer with tislelizumab plus chemotherapy versus chemotherapy alone

Adults aged 50 to 80 years with 20 pack-year smoking history who currently smoke or quit within last 15 years should be screened with low-dose CT